Royalty Pharma (RPRX)
(Real Time Quote from BATS)
$27.98 USD
-0.02 (-0.07%)
Updated Apr 29, 2024 11:56 AM ET
3-Hold of 5 3
C Value D Growth A Momentum C VGM
Fundamental Charts
About Price to Cash Flow
The Price to Cash Flow ratio or P/CF is price divided by its cash flow per share. It's another great way to determine whether a company is undervalued or overvalued with the denominator being cash flow. One of the reasons why some investors prefer the P/CF ratio over the P/E ratio is because the net income of the cash flow portion rightly adds depreciation and amortization back in since these are not cash expenditures. In contrast, the net income that goes into the earnings portion of the P/E ratio does not add these in, thus artificially reducing the income and skewing the P/E ratio. Like the P/E ratio, a lower number is considered better. A value under 20 is generally considered good.
RPRX 27.98 -0.02(-0.07%)
Will RPRX be a Portfolio Killer in April?
Zacks Investment Research is releasing its prediction for RPRX based on the 1-3 month trading system that more than doubles the S&P 500.
Zacks News for RPRX
Should You Invest in the iShares U.S. Pharmaceuticals ETF (IHE)?
Royalty Pharma (RPRX) Q4 Earnings: Taking a Look at Key Metrics Versus Estimates
RPRX: What are Zacks experts saying now?
Zacks Private Portfolio Services
RPRX or BX: Which Is the Better Value Stock Right Now?
TEVA, Royalty Pharma Sign Funding Deal for Schizophrenia Drug
Ryan Specialty Group (RYAN) Meets Q3 Earnings Estimates
Other News for RPRX
Royalty Pharma to Announce First Quarter 2024 Financial Results on May 9, 2024
Royalty Pharma Declares Second Quarter 2024 Dividend
Royalty Pharma declares $0.21 dividend
Royalty Pharma price target lowered by $2 at BofA, here's why
3 Pharma Stocks to Sell in April Before They Crash & Burn